Highest-materiality recent filing
Termination effective July 7, 2026, due to failure to close by the outside date under Section 9.1(b).
Aimei Health extends SPAC deadline to Aug 6, 2026 with $34,330.96 promissory note
Extension payment of $34,330.96 deposited into trust to extend termination date from July 6 to August 6, 2026.
Aimei Health Technology director Julianne Huh resigns, Daniel Polvi appointed
Julianne Huh resigned as director effective June 24, 2026, citing personal reasons with no disagreement.
Aimei Health extends SPAC deadline to July 6, 2026; issues $34,331 promissory note to sponsors
Extension from June 6, 2026 to July 6, 2026 funded by $34,330.96 deposited into trust account.
Aimei Health receives Nasdaq delisting notice for delayed Q1 10-Q
Notice received on May 19, 2026 for failure to file Q1 10-Q due May 15, 2026.
Eighteenth one-month extension from May 6 to June 6, 2026; $34,330.96 deposited into trust account.
Aimei Health receives Nasdaq delisting notice for late 10-K filing
Nasdaq notified Aimei on April 17, 2026 of non-compliance with Listing Rule 5250(c)(1) due to overdue Annual Report for FY2025.
Aimei Health extends business combination deadline to May 6, 2026; issues $34k promissory note
Extension payment of $34,330.96 deposited into trust to extend deadline by one month to May 6, 2026 (seventeenth extension).
Aimei Health extends SPAC deadline to Apr 6 2026 via $34K promissory note
Extension payment of $34,330.96 deposited into trust to extend deadline from March 6 to April 6, 2026.
Aimei Health extends business combination deadline to March 6, 2026; issues $34,331 promissory note
Deposited $34,330.96 into trust account to extend combination deadline by one month from Feb 6 to March 6, 2026 (fifteenth extension).
Aimei Health (AFJK) extends SPAC deadline to Feb 6, 2026 with $34k note from sponsor and target
Deposited $34,330.96 into trust to extend SPAC termination date from Jan 6 to Feb 6, 2026 (14th monthly extension).
Deposited $34,330.96 into trust to extend deadline from Dec 6, 2025 to Jan 6, 2026 (13th extension).
Aimei Health shareholders approve extension; 3.94M shares redeemed for ~$44.8M, trust drops to $0.7M
Shareholders approved extending business combination deadline from Dec 6, 2025 to Dec 6, 2026.
Aimei Health shareholders approve business combination with United Hydrogen; 3.95M shares redeemed
Business Combination Proposal passed with 70.80% of votes cast in favor (3,832,573 for, 1,580,804 against).
Aimei Health extends business combination deadline to Dec 6, 2025 with $150K trust deposit
Deposited $150,000 into trust for 12th and final extension from Nov 6 to Dec 6, 2025.
Aimei Health extends SPAC deadline to Nov 6 with $150K promissory note
$150,000 deposited into trust account to extend termination date from Oct 6 to Nov 6, 2025; tenth of 12 possible extensions.
Termination date pushed from Sept 6 to Oct 6, 2025 (10th of 12 permitted extensions).
Aimei Health (AFJK) issues $150K note for ninth trust extension to Sept 6, 2025
Extended deadline from Aug 6 to Sept 6, 2025; ninth of up to 12 allowed extensions.
Deposited $150,000 into trust to extend business combination deadline from July 6 to August 6, 2025 (eighth of 12 allowed extensions).
Aimei Health extends merger deadline with United Hydrogen to Sept 30, 2025
Amendment to Business Combination Agreement pushes Outside Date from March 31 to September 30, 2025.
Aimei Health SPAC extends deadline to July 6, 2025 with $150K note from sponsor and target
Seventh one-month extension from June 6 to July 6, 2025 funded by $150,000 deposit into trust account.
Aimei Health extends SPAC deadline to June 6, 2025 via $150K trust deposit
Deposited $150,000 into trust account to extend business combination deadline one month to June 6, 2025.
Termination date extended from April 6, 2025 to May 6, 2025; $150,000 deposited into trust for public shareholders.
Aimei Health extends SPAC deadline to April 6 with $150K promissory note from sponsors
Deposited $150,000 into trust for one-month extension from March 6 to April 6, 2025.
Aimei Health SPAC extends deadline to March 6, 2025; shareholders redeem 2.9M shares for $31.3M
Shareholders approved amendments to allow monthly extensions at $150,000 for all public shares (down from per-share amounts).
Aimei Health Technology adjourns EGM to Feb 5 due to lack of quorum
Extraordinary general meeting on Feb 4, 2025 failed to achieve quorum.
Deposited $227,700 into trust to extend termination date from Jan. 6 to Feb. 6, 2025.
Aimei Health shareholders reject trust amendment and adjournment proposals
Trust Amendment Proposal failed: 2,681,207 for, 4,676,800 against, 806,730 abstain (29.71% for, 51.81% against).
Aimei Health extends SPAC deadline to Jan 6, issues $227K promissory note
Deposited $227,000 ($0.033 per share) into trust to extend biz combination deadline from Dec 6, 2024 to Jan 6, 2024.
Aimei Health (AFJK) signs definitive merger agreement with United Hydrogen Group
Aimei Health (SPAC AFJK) entered into definitive Business Combination Agreement with United Hydrogen Group Inc. on June 19, 2024.
Aimei Health CEO Juan Fernandez Pascual resigns; Junheng Xie appointed
Juan Fernandez Pascual resigned as CEO, Secretary and director effective April 15, 2024.
Aimei Health Tech permits separate trading of ordinary shares and rights from Jan 22, 2024
Ordinary shares (AFJK) and rights (AFJKR) will trade separately on Nasdaq starting Jan 22, 2024.
Aimei Health Technology closes IPO of 6.9M units at $10.00, raising $69M; $69.7M placed in trust
IPO of 6,900,000 units at $10.00/unit, including full over-allotment; gross proceeds $69M.
Aimei Health Technology closes $69M SPAC IPO, including full over-allotment
Sold 6.9M units at $10/unit; gross proceeds $69M. Each unit = 1 ordinary share + 1 right (entitles 1/5 share).
On April 15, 2024, Juan Fernandez Pascual tendered to the board of directors of Aimei Health Technology Co., Ltd. (the “ Company ”) his resignation, effective as of that date, as Chief Executive Officer, Secretary and a director of the Company.
On April 19, 2024, the board of directors of the Company appointed Mr. Junheng Xie as the Chief Executive Officer, Secretary and a director of the Company with effect from April 15, 2024.
Max materiality 0.85 · Median 0.50 · Most common event other_material